Calpains and their multiple roles in diabetes mellitus

Annals of the New York Academy of Sciences

Volumn 1084, Issue , 2006, Pages 452-480

  Harris, Frederick ^a   Biswas, Suman ^b   Singh, Jaipaul ^a   Dennison, Sarah ^a   Phoenix, David A ^a  

^a UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

^b BRISTOL EYE HOSPITAL   (United Kingdom)

Author keywords

Calcium; Calpains; Cataract; Diabetes; Epithelial dysfunction; Insulin; Phenotype; Polymorphism

Indexed keywords

CALCIUM ION; CALPAIN; CALPAIN 10; CALPAIN 3; CALPAIN 5; CALPAIN I; CALPAIN II; GLUCOSE; GLUCOSE TRANSPORTER 4; HEAT SHOCK PROTEIN 90; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; NEUROGENIC DIFFERENTIATION FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RYANODINE RECEPTOR; UNCLASSIFIED DRUG; VIMENTIN;

ALZHEIMER DISEASE; BRAIN ISCHEMIA; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CATARACT; CATARACTOGENESIS; CELL STRAIN 3T3; CONFERENCE PAPER; DIABETIC RETINOPATHY; GENE LINKAGE DISEQUILIBRIUM; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HOMOZYGOSITY; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; LIPOGENESIS; LIPOLYSIS; MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OTSUKA LONG EVANS TOKUSHIMA FATTY RAT; PANCREAS ISLET BETA CELL; PARKINSON DISEASE; PHENOTYPE; PROTEIN DEGRADATION; RAT STRAIN; SIGNAL TRANSDUCTION; WISTAR RAT; ZUCKER DIABETIC FATTY RAT; ANIMAL; ENZYMOLOGY; GENETICS; PHYSIOLOGY; REVIEW;

ANIMALS; CALPAIN; DIABETES MELLITUS, TYPE 2; HUMANS; LINKAGE (GENETICS);

EID: 34447650074     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1372.011     Document Type: Conference Paper

References (195)

1. ZIMMET, P., K.G. ALBERTI & J. SHAW. 2001. Global and societal implications of the diabetes epidemic. Nature 414: 782-787.
2. KING, H., R.E. AUBERT & W.H. HERMAN. 1998. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21: 1414-1431.
3. SINHA, R. et al. 2002. Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N. Engl. J. Med. 346: 802-810.
4. GORODEZKY, C. et al. 2006. HLA and autoimmune diseases: type 1 diabetes (T1D) as an example. Autoimmun. Rev. 5: 187-194.
5. HANSEN, L. & O. PEDERSEN. 2005. Genetics of type 2 diabetes mellitus: status and perspectives. Diabetes Obes. Metab. 7: 122-135.
6. REDONDO, M.J. & G.S. EISENBARTH. 2002. Genetic control of autoimmunity in type I diabetes and associated disorders. Diabetologia 45: 605-622.
7. STUMVOLL, M., B.J. GOLDSTEIN & T.W. VAN HAEFTEN. 2005. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365: 1333-1346.
8. ADORINI, L., S. GREGORI & L.C. HARRISON. 2002. Understanding autoimmune diabetes: insights from mouse models. Trends Mol. Med. 8: 31-38.
9. CASTANO, L. & G.S. EISENBARTH. 1990. Type-I diabetes: a chronic autoimmune disease of human, mouse, and rat. Annu. Rev. Immunol. 8: 647-679.
10. BACH, J.F. 1994. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr. Rev. 15: 516-542.
11. CONCANNON, P. et al. 1998. A second-generation screen of the human genome for susceptibility to insulin-dependent diabetes mellitus. Nat. Genet. 19: 292-296.
12. HERR, M. et al. 2000. Evaluation of fine mapping strategies for a multifactorial disease locus: systematic linkage and association analysis of IDDM1 in the HLA region on chromosome 6p21. Hum. Mol. Genet. 9: 1291-1301.
13. ARNER, P. 2003. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol. Metab. 14: 137-145.
14. BAILEY, C.J. 1999. Insulin resistance and antidiabetic drugs. Biochem. Pharmacol. 58: 1511-1520.
15. BAILEY, C.J. 2000. Potential new treatments for type 2 diabetes. Trends Pharmacol. Sci. 21: 259-265.
16. PETERSEN, K.F. & G.I. SHULMAN. 2002. Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am. J. Cardiol. 90: 11G-18G.
17. SACKS, D.B. & J.M. MCDONALD. 1996. The pathogenesis of type II diabetes mellitus. A polygenic disease. Am. J. Clin. Pathol. 105: 149-156.
18. SCHEEN, A.J. & F.H. LUYCKX. 2002. Obesity and liver disease. Best Pract. Res. Clin. Endocrinol. Metab. 16: 703-716.
19. BALEN, A. & M. RAJKOWHA. 2003. Polycystic ovary syndrome - a systemic disorder? Best Pract. Res. Clin. Obstet. Gynaecol. 17: 263-274.
20. NAOUMOVA, R.P. & D.J. BETTERIDGE. 2002. A new drug target for treatment of dyslipidaemia associated with type 2 diabetes and the metabolic syndrome? Lancet 359: 2215-2216.
21. CONLIN, P.R. 2001. Efficacy and safety of angiotensin receptor blockers: a review of losartan in essential hypertension. Curr. Ther. Res. 62: 79-91.
22. PLUTZKY, J., G. VIBERTI & S. HAFFNER. 2002. Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. J. Diabetes Complicat. 16: 401-415.
23. ALI RAZA, J. & A. MOVAHED. 2003. Current concepts of cardiovascular diseases in diabetes mellitus. Int. J. Cardiol. 89: 123-134.
24. ZANELLA, M.T. & A.B. RIBEIRO. 2002. The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies. Clin. Ther. 24: 1019-1034.
25. GARDNER, T.W. et al. 2002. Diabetic retinopathy: more than meets the eye. Surv. Ophthalmol. 47(Suppl 2): S253-S262.
26. COPPINI, D.V. et al. 2000. Showing neuropathy is related to increased mortality in diabetic patients - a survival analysis using an accelerated failure time model. J. Clin. Epidemiol. 53: 519-523.
27. BARROSO, I. 2005. Genetics of type 2 diabetes. Diabet. Med. 22: 517-535.
28. GLOYN, A.L. 2003. The search for type 2 diabetes genes. Ageing Res. Rev. 2: 111-127.
29. FROGUEL, P. et al. 1992. Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. Nature 356: 162-164.
30. HATTERSLEY, A.T. et al. 1992. Linkage of type 2 diabetes to the glucokinase gene. Lancet 339: 1307-1310.
31. HORIKAWA, Y. et al. 2000. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat. Genet. 26: 163-175.
32. SUZUKI, K. et al. 2004. Structure, activation, and biology of calpain. Diabetes 53: S12-S18.
33. TURNER, M.D., P.G. CASSELL & G.A. HITMAN. 2005. Calpain-10: from genome search to function. Diabetes Metab. Res. Rev. 21: 505-514.
34. GOLL, D.E. et al. 2003. The calpain system. Physiol. Rev. 83: 731-801.
35. HOSFIELD, C.M. et al. 1999. Crystal structure of calpain reveals the structural basis for Ca(2+)-dependent protease activity and a novel mode of enzyme activation. EMBO J. 18: 6880-6889.
36. STROBL, S. et al. 2000. The crystal structure of calcium-free human m-calpain suggests an electrostatic switch mechanism for activation by calcium. Proc. Natl. Acad. Sci. USA 97: 588-592.
37. HOSFIELD, C.M., J.S. ELCE & Z. JIA. 2004. Activation of calpain by Ca2+: roles of the large subunit N-terminal and domain III-IV linker peptides. J. Mol. Biol. 343: 1049-1053.
38. HATA, S. et al. 2001. Domain II of m-calpain is a Ca(2+)-dependent cysteine protease. FEBS Lett. 501: 111-114.
39. TOMPA, P. et al. 2001. Domain III of calpain is a Ca2+-regulated phospholipid-binding domain. Biochem. Biophys. Res. Commun. 280: 1333-1339.
40. DUTT, P. et al. 2000. Roles of individual EF-hands in the activation of m-calpain by calcium. Biochem. J. 348(Pt 1): 37-43.
41. KRETSINGER, R.H. 1997. EF-hands embrace. Nat. Struct. Biol. 4: 514-516.
42. ARTHUR, J.S. & C. CRAWFORD. 1996. Investigation of the interaction of m-calpain with phospholipids: calpain-phospholipid interactions. Biochim. Biophys. Acta 1293: 201-206.
43. DENNISON, S.R. et al. 2005. Investigations into the membrane interactions of m-calpain domain V. Biophys. J. 88: 3008-3017.
44. REVERTER, D., H. SORIMACHI & W. BODE. 2001. The structure of calcium-free human m-calpain: implications for calcium activation and function. Trends Cardiovasc. Med. 11: 222-229.
45. REVERTER, D. et al. 2001. Structural basis for possible calcium-induced activation mechanisms of calpains. Biol. Chem. 382: 753-766.
46. REVERTER, D. et al. 2002. Flexibility analysis and structure comparison of two crystal forms of calcium-free human m-calpain. Biol. Chem. 383: 1415-1422.
47. ALEXA, A. et al. 2004. Contribution of distinct structural elements to activation of calpain by Ca2+ ions. J. Biol. Chem. 279: 20118-20126.
48. BOZOKY, Z. et al. 2005. Multiple interactions of the 'transducer' govern its function in calpain activation by Ca2+. Biochem. J. 388: 741-744.
49. HOSFIELD, C.M. et al. 2001. Calpain mutants with increased Ca2+ sensitivity and implications for the role of the C(2)-like domain. J. Biol. Chem. 276: 7404-7407.
50. MOLDOVEANU, T. et al. 2001. Ca(2+)-induced structural changes in rat m-calpain revealed by partial proteolysis. Biochim. Biophys. Acta. 1545: 245-254.
51. BRANCA, D. 2004. Calpain-related diseases. Biochem. Biophys. Res. Commun. 322: 1098-1104.
52. 2+ Dependency of calpain 3 (p94) activation. Biochemistry 45: 3714-3722.
53. HUANG, Y. & K.K. WANG. 2001. The calpain family and human disease. Trends Mol. Med. 7: 355-362.
54. SORIMACHI, H. & K. SUZUKI. 2001. The structure of calpain. J. Biochem. (Tokyo) 129: 653-664.
55. CARAFOLI, E. & M. MOLINARI. 1998. Calpain: a protease in search of a function? Biochem. Biophys. Res. Commun. 247: 193-203.
56. SATO, K. & S. KAWASHIMA. 2001. Calpain function in the modulation of signal transduction molecules. Biol. Chem. 382: 743-751.
57. YAJIMA, Y. & S. KAWASHIMA. 2002. Calpain function in the differentiation of mesenchymal stem cells. Biol. Chem. 383: 757-764.
58. RAMI, A. 2003. Ischemic neuronal death in the rat hippocampus: the calpaincalpastatin-caspase hypothesis. Neurobiol. Dis. 13: 75-88.
59. YAMASHIMA, T. 2000. Implication of cysteine proteases calpain, cathepsin and caspase in ischemic neuronal death of primates. Prog. Neurobiol. 62: 273-295.
60. CARRAGHER, N.O. 2006. Calpain inhibition: a therapeutic strategy targeting multiple disease states. Curr. Pharm. Des. 12: 615-638.
61. SAZONTOVA, T.G., A.A. MATSKEVICH & Y.V. ARKHIPENKO. 1999. Calpains: physiological and pathophysiological significance. Pathophysiology 6: 91-102.
62. BARTOLI, M. & I. RICHARD. 2005. Calpains in muscle wasting. Int. J. Biochem. Cell. Biol. 37: 2115-2133.
63. NIXON, R.A. 2000. A "protease activation cascade" in the pathogenesis of Alzheimer's disease. Ann. N. Y. Acad. Sci. 924: 117-131.
64. VANDERKLISH, P.W. & B.A. BAHR. 2000. The pathogenic activation of calpain: a marker and mediator of cellular toxicity and disease states. Int. J. Exp. Pathol. 81: 323-339.
65. HARRIS, F. et al. 2004. Role of calpains in diabetes mellitus: a mini review. Mol. Cell. Biochem. 261: 161-167.
66. HANIS, C.L. et al. 1996. A genome-wide search for human non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2. Nat. Genet. 13: 161-166.
67. GARANT, M.J. et al. 2002. SNP43 of CAPN10 and the risk of type 2 diabetes in African Americans: the Atherosclerosis Risk in Communities Study. Diabetes 51: 231-237.
68. LEIPOLD, H. et al. 2004. Calpain-10 haplotype combination and association with gestational diabetes mellitus. Obstet. Gynecol. 103: 1235-1240.
69. LYNN, S. et al. 2002. Variation in the calpain-10 gene affects blood glucose levels in the British population. Diabetes 51: 247-250.
70. MALECKI, M.T. et al. 2002. Homozygous combination of calpain 10 gene haplotypes is associated with type 2 diabetes mellitus in a Polish population. Eur. J. Endocrinol. 146: 695-699.
71. ORHO-MELANDER, M. et al. 2002. Variants in the calpain-10 gene predispose to insulin resistance and elevated free fatty acid levels. Diabetes 51: 2658-2664.
72. BAIER, L.J. et al. 2000. A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance. J. Clin. Invest. 106: 69-73.
73. CASSELL, P.G. et al. 2002. Haplotype combinations of calpain 10 gene polymorphisms associate with increased risk of impaired glucose tolerance and type 2 diabetes in South Indians. Diabetes 51: 1622-1628.
74. WEEDON, M.N. et al. 2003. Meta-analysis and a large association study confirm a role for calpain-10 variation in type 2 diabetes susceptibility. Am. J. Hum. Genet. 73: 1208-1212.
75. NG, M.C.Y. et al. 2001. Association of calpain 10 genetic polymorphisms with type 2 diabetes and insulin response in non-diabetic Chinese. Diabetes 50: A234.
76. FURUTA, M., H. FURUTA & K. UEDA. 2001. Relationship between genetic variation in the calpain 10 gene and insulin sensitivity in Japanese. Diabetes 50: A490.
77. DAIMON, M. et al. 2002. Calpain 10 gene polymorphisms are related, not to type 2 diabetes, but to increased serum cholesterol in Japanese. Diabetes Res. Clin. Pract. 56: 147-152.
78. ELBEIN, S.C. et al. 2002. Role of calpain-10 gene variants in familial type 2 diabetes in Caucasians. J. Clin. Endocrinol. Metab. 87: 650-654.
79. EVANS, J.C. et al. 2001. Studies of association between the gene for calpain-10 and type 2 diabetes mellitus in the United Kingdom. Am. J. Hum. Genet. 69: 544-552.
80. FINGERLIN, T.E. et al. 2002. Variation in three single nucleotide polymorphisms in the calpain-10 gene not associated with type 2 diabetes in a large Finnish cohort. Diabetes 51: 1644-1648.
81. HEGELE, R.A. et al. 2001. Absence of association of type 2 diabetes with CAPN10 and PC-1 polymorphisms in Oji-Cree. Diabetes Care 24: 1498-1499.
82. HORIKAWA, Y. et al. 2003. Genetic variations in calpain-10 gene are not a major factor in the occurrence of type 2 diabetes in Japanese. J. Clin. Endocrinol. Metab. 88: 244-247.
83. RASMUSSEN, S.K. et al. 2002.Variants within the calpain-10 gene on chromosome 2q37 (NIDDM1) and relationships to type 2 diabetes, insulin resistance, and impaired acute insulin secretion among Scandinavian Caucasians. Diabetes 51: 3561-3567.
84. SUN, H.X. et al. 2002. Single nucleotide polymorphisms in CAPN10 gene of Chinese people and its correlation with type 2 diabetes mellitus in Han people of northern China. Biomed. Environ. Sci. 15: 75-82.
85. TSAI, H.J. et al. 2001. Type 2 diabetes and three calpain-10 gene polymorphisms in Samoans: no evidence of association. Am. J. Hum. Genet. 69: 1236-1244.
86. XIANG, K. et al. 2001. The impact of calpain-10 gene combined-SNP variation on type 2 diabetes mellitus and its related metabolic traits. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 18: 426-430.
87. COX, N.J. et al. 2004. Linkage of calpain 10 to type 2 diabetes: the biological rationale. Diabetes 53(Suppl 1): 19-25.
88. RIDDERSTRALE, M., H. PARIKH & L. GROOP. 2005. Calpain 10 and type 2 diabetes: are we getting closer to an explanation? Curr. Opin. Clin. Nutr. Metab. Care 8: 361-366.
89. SONG, Y. et al. 2004. Are variants in the CAPN10 gene related to risk of type 2 diabetes? A quantitative assessment of population and family-based association studies. Am. J. Hum. Genet. 74: 208-222.
90. PARIKH, H. & L. GROOP. 2004. Candidate genes for type 2 diabetes. Rev. Endocr. Metab. Disord. 5: 151-176.
91. LYSSENKO, V. et al. 2005. Genetic prediction of future type 2 diabetes. PLoS Med. 2: 1299-1308.
92. SUN, L., N.J. COX & M.S. MCPEEK. 2002.Astatistical method for identification of polymorphisms that explain a linkage result. Am. J. Hum. Genet. 70: 399-411.
93. COX, N.J. et al. 1999. Loci on chromosomes 2 (NIDDM1) and 15 interact to increase susceptibility to diabetes in Mexican Americans. Nat. Genet. 21: 213-215.
94. WALDER, K. et al. 2002. Calpain 3 gene expression in skeletal muscle is associated with body fat content and measures of insulin resistance. Int. J. Obes. Relat. Metab. Disord. 26: 442-449.
95. TSCHRITTER, O. et al. 2003. Assessing the shape of the glucose curve during an oral glucose tolerance test. Diabetes Care 26: 1026-1033.
96. STUMVOLL, M. et al. 2001. Functional significance of the UCSNP-43 polymorphism in the CAPN10 gene for proinsulin processing and insulin secretion in nondiabetic Germans. Diabetes 50: 2161-2163.
97. WEYER, C. et al. 2000. A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia. Diabetes 49: 2094-2101.
98. SHORE, A.C. et al. 2002. Association of calpain-10 gene with microvascular function. Diabetologia 45: 899-904.
99. KNOWLER, W.C. et al. 1978. Diabetes incidence and prevalence in Pima Indians: a 19-fold greater incidence than in Rochester, Minnesota. Am. J. Epidemiol. 108: 497-505.
100. CARLSSON, E. et al. 2005. Genetic and nongenetic regulation of CAPN10 mRNA expression in skeletal muscle. Diabetes 54: 3015-3020.
101. MA, H. et al. 2001. Characterization and expression of calpain 10. A novel ubiquitous calpain with nuclear localization. J. Biol. Chem. 276: 28525-28531.
102. YANG, X. et al. 2001. Reduced skeletal muscle calpain-10 transcript level is due to a cumulative decrease in major isoforms. Mol. Genet. Metab. 73: 111-113.
103. COX, N.J. 2001. Challenges in identifying genetic variation affecting susceptibility to type 2 diabetes: examples from studies of the calpain-10 gene. Hum. Mol. Genet. 10: 2301-2305.
104. LEAHY, J.L. 2005. Pathogenesis of type 2 diabetes mellitus. Arch. Med. Res. 36: 197-209.
105. SHIMA, Y. et al. 2003. Association of the SNP-19 genotype 22 in the calpain-10 gene with elevated body mass index and hemoglobin A1c levels in Japanese. Clin. Chim. Acta 336: 89-96.
106. JI, L., L. CHEN & X. HAN. 2001. The role of calpain10 gene polymorphisms in genetic susceptibility to type 2 diabetes in a Chinese population. Diabetes 50: A206-A207.
107. SUGIMOTO, K. et al. 2003. UCSNP-43 G/A polymorphism of calpain-10 gene is associated with hypertension and dyslipidemia in Japanese population. Am. J. Hypertens. 16: A82.
108. CARLSSON, E. et al. 2004. Variation in the calpain-10 gene is associated with elevated triglyceride levels and reduced adipose tissue messenger ribonucleic acid expression in obese Swedish subjects. J. Clin. Endocrinol. Metab. 89: 3601-3605.
109. HINNEY, A. et al. 2002. No evidence for involvement of the calpain-10 gene 'high-risk' haplotype combination for non-insulin-dependent diabetes mellitus in early onset obesity. Mol. Genet. Metab. 76: 152-156.
110. MURAMATSU, Y. et al. 2003. Capn10, a candidate gene responsible for type 2 diabetes mellitus in the OLETF rat. IUBMB Life 55: 533-537.
111. OVALLE, F. & R. AZZIZ. 2002. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil. Steril. 77: 1095-1105.
112. EHRMANN, D.A. et al. 2002. Relationship of calpain-10 genotype to phenotypic features of polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 87: 1669-1673.
113. GONZALEZ, A. et al. 2002. Comment: CAPN10 alleles are associated with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 87: 3971-3976.
114. ESCOBAR-MORREALE, H.F. et al. 2002. Common single nucleotide polymorphisms in intron 3 of the calpain-10 gene influence hirsutism. Fertil. Steril. 77: 581-587.
115. HADDAD, L. et al. 2002. Variation within the type 2 diabetes susceptibility gene calpain-10 and polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 87: 2606-2610.
116. PATEL, Y.M. & M.D. LANE. 1999. Role of calpain in adipocyte differentiation. Proc. Natl. Acad. Sci. USA 96: 1279-1284.
117. SMITH, L.K., K.M. RICE & C.W. GARNER. 1996. The insulin-induced down-regulation of IRS-1 in 3T3-L1 adipocytes is mediated by a calcium-dependent thiol protease. Mol. Cell. Endocrinol. 122: 81-92.
118. ZHANG, H., H. HOFF & C. SELL. 2003. Downregulation of IRS-1 protein in thapsigargin-treated human prostate epithelial cells. Exp. Cell. Res. 289: 352-358.
119. HOFFSTEDT, J., E. NASLUND & P. ARNER. 2002. Calpain-10 gene polymorphism is associated with reduced beta(3)-adrenoceptor function in human fat cells. J. Clin. Endocrinol. Metab. 87: 3362-3367.
120. HOFFSTEDT, J. et al. 2002. Polymorphism in the calpain 10 gene influences glucose metabolism in human fat cells. Diabetologia 45: 276-282.
121. RORSMAN, P. & E. RENSTROM. 2003. Insulin granule dynamics in pancreatic beta cells. Diabetologia 46: 1029-1045.
122. ZHOU, Y.P. et al. 2003. A 48-hour exposure of pancreatic islets to calpain inhibitors impairs mitochondrial fuel metabolism and the exocytosis of insulin. Metabolism 52: 528-534.
123. SREENAN, S.K. et al. 2001. Calpains play a role in insulin secretion and action. Diabetes 50: 2013-2020.
124. JOHNSON, J.D. et al. 2004. RyR2 and calpain-10 delineate a novel apoptosis pathway in pancreatic islets. J. Biol. Chem. 279: 24794-24802.
125. PARNAUD, G. et al. 2005. Inhibition of calpain blocks pancreatic beta-cell spreading and insulin secretion. Am. J. Physiol. Endocrinol. Metab. 289: 313-321.
126. PELHAM, H.R. 2001. SNAREs and the specificity of membrane fusion. Trends Cell. Biol. 11: 99-101.
127. HAY, J.C. 2001. SNARE complex structure and function. Exp. Cell. Res. 271: 10-21.
128. CHEN, Y.A. & R.H. SCHELLER. 2001. SNARE-mediated membrane fusion. Nat. Rev. Mol. Cell. Biol. 2: 98-106.
129. ROTHMAN, J.E. 1994. Mechanisms of intracellular protein transport. Nature 372: 55-63.
130. OHARA-IMAIZUMI, M. et al. 2004. Correlation of syntaxin-1 and SNAP-25 clusters with docking and fusion of insulin granules analysed by total internal reflection fluorescence microscopy. Diabetologia 47: 2200-2207.
131. MARSHALL, C. et al. 2005. Evidence that an isoform of calpain-10 is a regulator of exocytosis in pancreatic beta-cells. Mol. Endocrinol. 19: 213-224.
132. JOHNSON, J.D. et al. 2004. Ryanodine receptors in human pancreatic β cells: localization and effects on insulin secretion. FASEB J. 10: 878-880.
133. MAEDLER, K. et al. 2002. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J. Clin. Invest. 110: 851-860.
134. ZHOU, Y.P. et al. 1998. Apoptosis in insulin-secreting cells. Evidence for the role of intracellular Ca2+ stores and arachidonic acid metabolism. J. Clin. Invest. 101: 1623-1632.
135. CUSHMAN, S.W. & L.J. WARDZALA. 1980. Potential mechanism of insulin action on glucose transport in the isolated rat adipose cell. Apparent translocation of intracellular transport systems to the plasma membrane. J. Biol. Chem. 255: 4758-4762.
136. BUTLER, P.C. et al. 1990. Effect of insulin on oxidation of intracellularly and extracellularly derived glucose in patients with NIDDM. Evidence for primary defect in glucose transport and/or phosphorylation but not oxidation. Diabetes 39: 1373-1380.
137. CLINE, G.W. et al. 1999. Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N. Engl. J. Med. 341: 240-246.
138. ROTHMAN, D.L., R.G. SHULMAN & G.I. SHULMAN. 1992. 31P nuclear magnetic resonance measurements of muscle glucose-6-phosphate. Evidence for reduced insulin-dependent muscle glucose transport or phosphorylation activity in non-insulin-dependent diabetes mellitus. J. Clin. Invest. 89: 1069-1075.
139. WENDT, A., V.F. THOMPSON & D.E. GOLL. 2004. Interaction of calpastatin with calpain: a review. Biol. Chem. 385: 465-472.
140. OTANI, K. et al. 2004. Calpain system regulates muscle mass and glucose transporter GLUT4 turnover. J. Biol. Chem. 279: 20915-20920.
141. PAUL, D.S. et al. 2003. Calpain facilitates GLUT4 vesicle translocation during insulin-stimulated glucose uptake in adipocytes. Biochem. J. 376: 625-632.
142. COOKE, D.W. & Y.M. PATEL. 2005. GLUT4 expression in 3T3-L1 adipocytes is repressed by proteasome inhibition, but not by inhibition of calpains. Mol. Cell. Endocrinol. 232: 37-45.
143. VARUGHESE, G.I., J. TOMSON & G.Y.H. LIP. 2005. Type 2 diabetes mellitus: a cardiovascular perspective. Int. J. Clin. Pract. 59: 798-816.
144. AVOGARO, A. et al. 2006. Endothelial dysfunction in type 2 diabetes mellitus. Nutr. Metab. Cardiovasc. Dis. 16: 39-45.
145. STALKER, T.J., C.B. SKVARKA & R. SCALIA. 2003. A novel role for calpains in the endothelial dysfunction of hyperglycemia. FASEB J. 17: 1511-1513.
146. KOBAYASHI, S., T. NAITOH & M. KIMURA. 1989. Diabetic state-induced regulation of glucose uptake to skeletal muscle by insulin: a possible mechanism of its enhancement and autoinhibition. Diabetes Res. Clin. Pract. 7(Suppl 1): S11-S13.
147. SRIVASTAVA, K. & D. DASH. 2002. Changes in membrane microenvironment and signal transduction in platelets from NIDDM patients - a pilot study. Clin. Chim. Acta 317: 213-220.
148. STALKER, T.J., Y. GONG & R. SCALIA. 2005. The calcium-dependent protease calpain causes endothelial dysfunction in type 2 diabetes. Diabetes 54: 1132-1140.
149. DANDONA, P. et al. 2004. Endothelial dysfunction, inflammation and diabetes. Rev. Endocr. Metab. Disord. 5: 189-197.
150. COSENTINO, F. & G.E. ASSENZA. 2004. Diabetes and inflammation. Herz 29: 749-759.
151. LEFER, A.M. & R. SCALIA. 2001. Nitric oxide in inflammation. In Physiology of Inflammation. K. Ley, Ed.: 447-472 Oxford University Press. Oxford, UK.
152. FONTANA, J. et al. 2002. Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release. Circ. Res. 90: 866-873.
153. BELLOCQ, A. et al. 1999. Somatostatin increases glucocorticoid binding and signaling in macrophages by blocking the calpain-specific cleavage of Hsp 90. J. Biol. Chem. 274: 36891-36896.
154. MINAMI, Y. et al. 1994. The carboxy-terminal region of mammalian HSP90 is required for its dimerization and function in vivo. Mol. Cell. Biol. 14: 1459-1464.
155. SU, Y.C. & E.R. BLOCK. 2000. Role of calpain in hypoxic inhibition of nitric oxide synthase activity in pulmonary endothelial cells. Am. J. Physiol. - Lung Cell. Mol. Physiol. 278: L1204-L1212.
156. SHEARER, T.R. et al. 2000. Calpains in the lens and cataractogenesis. Methods Mol. Biol. 144: 277-285.
157. MA, H. et al. 1998. Cloning and expression of mRNA for calpain Lp82 from rat lens: splice variant of p94. Invest. Ophthalmol. Vis. Sci. 39: 454-461.
158. MA, H. et al. 1998. Protein for Lp82 calpain is expressed and enzymatically active in young rat lens. Exp. Eye Res. 67: 221-229.
159. SHIH, M. et al. 2006. Biochemical properties of lens-specific calpain Lp85. Exp. Eye Res. 82: 146-152.
160. MA, H. et al. 2000. Lp85 calpain is an enzymatically active rodent-specific isozyme of lens Lp82. Curr. Eye Res. 20: 183-189.
161. AZUMA, M. et al. 2000. Identification and characterization of a retina-specific calpain (Rt88) from rat. Curr. Eye Res. 21: 710-720.
162. NAKAJIMA, T. et al. 2001. Different expression patterns for ubiquitous calpains and Capn3 splice variants in monkey ocular tissues. Biochim. Biophys. Acta 1519: 55-64.
163. CIULLA, T.A., A.G. AMADOR & B. ZINMAN. 2003. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 26: 2653-2664.
164. AZUMA, M. et al. 2004. Involvement of calpain isoforms in retinal degeneration in WBN/Kob rats. Comp. Med. 54: 533-542.
165. NAKAMA, K. et al. 1985. Spontaneous diabetes-like syndrome in WBN/KOB rats. Acta Diabetol. Lat. 22: 335-342.
166. ROY, K. et al. 2005. Effects of streptozotocin-induced type 1 diabetes mellitus on protein and ion concentrations in ocular tissues of the rat. Int. J. Diabetes Metab. 13: 154-158.
167. KYSELOVA, Z., M. STEFEK & V. BAUER. 2004. Pharmacological prevention of diabetic cataract. J. Diabetes Complicat 18: 129-140.
168. BISWAS, S. et al. 2005. Calpains: enzymes of vision? Med. Sci. Monit. 11:RA301-RA310.
169. LOU, M.F. 2003. Redox regulation in the lens. Prog. Retin. Eye Res. 22: 657-682.
170. STITT, A.W. 2001. Advanced glycation: an important pathological event in diabetic and age related ocular disease. Br. J. Ophthalmol. 85: 746-753.
171. SAKAMOTO-MIZUTANI, K. et al. 2002. Contribution of ubiquitous calpains to cataractogenesis in the spontaneous diabetic WBN/Kob rat. Exp. Eye Res. 75: 611-617.
172. SHEARER, T.R. et al. 1997. Selenite nuclear cataract: review of the model. Mol. Vis. 3: 8.
173. REED, N.A. et al. 2003. Protein expression patterns for ubiquitous and tissue specific calpains in the developing mouse lens. Exp. Eye Res. 76: 433-443.
174. MA, H. et al. 2000. Influence of specific regions in Lp82 calpain on protein stability, activity, and localization within lens. Invest. Ophthalmol. Vis. Sci. 41: 4232-4239.
175. UEDA, Y., M.K. DUNCAN & L.L. DAVID. 2002. Lens proteomics: the accumulation of crystallin modifications in the mouse lens with age. Invest. Ophthalmol. Vis. Sci. 43: 205-215.
176. MA, H. et al. 1999. Lp82 is the dominant form of calpain in young mouse lens. Exp. Eye Res. 68: 447-456.
177. BARUCH, A. et al. 2001. Defining a link between gap junction communication, proteolysis, and cataract formation. J. Biol. Chem. 276: 28999-29006.
178. AZUMA, M. et al. 2003. Differential influence of proteolysis by calpain 2 and Lp82 on in vitro precipitation of mouse lens crystallins. Biochem. Biophys. Res. Commun. 307: 558-563.
179. UEDA, Y. et al. 2002. Mass measurements of C-terminally truncated alpha-crystallins from two-dimensional gels identify Lp82 as a major endopeptidase in rat lens. Mol. Cell. Proteom. 1: 357-365.
180. SHARMA, K.K., K. KESTER & N. ELSER. 1996. Identification of new lens protease( s) using peptide substrates having in vivo cleavage sites. Biochem. Biophys. Res. Commun. 218: 365-370.
181. TAKEMOTO, L. 1994. Release of [alpha]-A sequence 158-173 correlates with a decrease in the molecular chaperone properties of native [alpha]-crystallin. Exp. Eye Res. 59: 239-242.
182. UEDA, Y. et al. 2001. Purification and characterization of lens specific calpain (Lp82) from bovine lens. Exp. Eye Res. 73: 625-637.
183. FOUGEROUSSE, F. et al. 2000. Human-mouse differences in the embryonic expression patterns of developmental control genes and disease genes. Hum. Mol. Genet. 9: 165-173.
184. COLVIS, C.M. et al. 2000. Tracking pathology with proteomics: identification of in vivo degradation products of alphaB-crystallin. Electrophoresis 21: 2219-2227.
185. LUND, A.L., J.B. SMITH & D.L. SMITH. 1996. Modifications of thewater-insoluble human lens alpha-crystallins. Exp. Eye Res. 63: 661-672.
186. TAKEMOTO, L.J. 1995. Identification of the in vivo truncation sites at the C-terminal region of alpha-A crystallin from aged bovine and human lens. Curr. Eye Res. 14: 837-841.
187. ANDERSSON, M., J. SJOSTRAND & J.O. KARLSSON. 1996. Calpains in the human lens: relations to membranes and possible role in cataract formation. Ophthalmic Res. 28(Suppl 1): 51-54.
188. AZUMA, M. et al. 1997. Activation of calpain in lens: a review and proposed mechanism. Exp. Eye Res. 64: 529-538.
189. INOMATA, M. et al. 2000. Aminoguanidine-treatment results in the inhibition of lens opacification and calpain-mediated proteolysis in Shumiya cataract rats (SCR). J. Biochem. (Tokyo) 128: 771-776.
190. THAMPI, P. et al. 2002. Enhanced C-terminal truncation of alphaA- and alphaB-crystallins in diabetic lenses. Invest. Ophthalmol. Vis. Sci. 43: 3265-3272.
191. FUKIAGE, C. et al. 1997. SJA6017, a newly synthesized peptide aldehyde inhibitor of calpain: amelioration of cataract in cultured rat lenses. Biochim. Biophys. Acta 1361: 304-312.
192. BISWAS, S. et al. 2004. The in vitro retardation of porcine cataractogenesis by the calpain inhibitor, SJA6017. Mol. Cell. Biochem. 261: 169-173.
193. ANDERSSON, M. et al. 1994. Calpains in lens epithelium from patients with cataract. Exp. Eye Res. 59: 359-364.
194. SANDERSON, J., J.M. MARCANTONIO & G. DUNCAN. 2000. A human lens model of cortical cataract: Ca2+-induced protein loss, vimentin cleavage and opacification. Invest. Ophthalmol. Vis. Sci. 41: 2255-2261.
195. THAMPI, P., S. ZARINA & E.C. ABRAHAM. 2002. Alpha-crystallin chaperone function in diabetic rat and human lenses. Mol. Cell. Biochem. 229: 113-118.